

EUROPEAN PATENT APPLICATION

Application number: 85307044.9

Date of filing: 02.10.85

Int. Cl. 4: **C 12 N 15/00**
C 07 H 21/04, C 12 P 21/00
C 12 P 21/02, C 07 K 15/00
C 07 K 13/00, C 12 N 5/00
//C12R1:19

Priority: 05.10.84 US 658342
 05.10.84 US 658339
 05.10.84 US 658095

Date of publication of application:
 09.04.86 Bulletin 86/15

Designated Contracting States:
 AT BE CH DE FR GB IT LI LU NL SE

Applicant: GENENTECH, INC.
 460 Point San Bruno Boulevard
 South San Francisco California 94080(US)

Inventor: Bochner, Barry Ronald
 2904 Lincoln Avenue
 Alameda California 94501(US)

Inventor: Chang, Chung-Nan
 231 Rosalie Street
 San Mateo California 94403(US)

Inventor: Gray, Gregory Lawrence
 530 Elm court
 South San Francisco California 94080(US)

Inventor: Heyneker, Herbert Louis
 501 Roehampton Road
 Hillsborough California 94010(US)

Inventor: McFarland, Nancy Chadwick
 2019 Whiteoak Way
 San Carlos California 94070(US)

Inventor: Olson, Kenneth Charles
 3036 Hillside Drive
 Burlingame California 94010(US)

Inventor: Pai, Rong-Chang
 1136 Blythe Street
 Foster City California 94404(US)

Inventor: Rey, Michael Willard
 611 A Prospect Row
 San Mateo California 94403(US)

Representative: Armitage, Ian Michael et al,
 MEWBURN ELLIS & CO. 2/3 Cursitor Street
 London EC4A 1BQ(GB)

DNA, cell cultures and methods for the secretion of heterologous proteins and periplasmic protein recovery.

Direct linkage of DNA encoding prokaryotic signals such as *E. coli* enterotoxin with DNA encoding mature eukaryotic proteins, followed by transformation and culture of bacterial hosts characterized by a periplasmic space, yields substantial amounts of periplasmic mature protein. Constitutively promoted gram negative bacterial mutants are transformed with vectors containing DNA encoding a secretable heterologous protein under the transcriptional control of a constitutively promoted promoter. Periplasmic proteins are recovered from transformed gram negative bacteria by a process comprising freezing and thawing the cells. Advantages are obtained by culturing the cells in phosphate-limiting media and by killing the cells prior to separation of periplasmic proteins.




Fig.3.

5

-1-

10

DNA, CELL CULTURES AND METHODS FOR THE
SECRETION OF HETEROLOGOUS PROTEINS
AND PERIPLASMIC PROTEIN RECOVERY

15

20

This application relates to methods for manufacturing proteins in bacteria. It particularly is concerned with isolating eukaryotic proteins from the periplasm of transformed bacteria while minimizing proteolytic degradation of the protein and contamination by nonperiplasmic proteins. This application also relates to the synthesis of mature eukaryotic proteins in bacterial hosts. It is directed to providing vectors that will express hybrid preproteins in high yields in host cells, cleave the signal sequence from the preprotein and secrete mature eukaryotic protein in the periplasmic space of the host cells.

25

30

35

Literature that should be consulted in regard to this application is U.S. patent 4,375,514 and 4,411,994; U.K. patent application 2,091,268A (published 1982); I. Palva et al., "Gene" 22: 229-235 (1983); H. Inouye et al., "J. Bact" 148(2): 434-439 (1983); K. Talmadge et al., "P.N.A.S. USA" 77(7): 3988-3992 (1980); K. Talmadge et al., "P.N.A.S. USA" 77(6): 3369-3373 (1980); European Patent Application 114,695; R. Picken et al., "Infection and Immunity" 42(1): 269-275 (1983); T. Silhavy et al., "Microbiological Reviews" 47(3): 313-344 (Sept. 1983); J. Kadonaga et al., "J. Biol. Chem." 259(4): 2149-2154 (Feb. 1984); International PCT application

WO 84/00774 (Mar. 1984); O. Zemel-Dreassen et al., "Gene" 27:
315-322 (1984); S. Michaelis et al., "J. Bact." 154(1): 366-374
(Apr. 1983); European Patent Application 114,695 (published Aug. 1,
1984); and G. Gray et al., "Biotechnology" pp 161-165 (Feb. 1984).

5 Many naturally occurring secretory and membrane proteins
are initially synthesized as nascent or intracellular preproteins.
These are proteins in which a "signal" polypeptide is linked to the
amino acid residue that will become the amino terminus of the mature
protein upon secretion. The signal polypeptide is a peptide
10 sequence which enables the mature protein to pass through the
cellular membrane of the cell. The signal peptide is cleaved away,
or "processed", in passing through the cellular membrane by a
mechanism that is under study. If the processing occurs properly
the mature protein will be free of any amino terminal extraneous
15 signal amino acid residues and will have the proper amino terminal
amino acid. Thus, if a heterologous gene which includes the DNA
encoding a signal sequence is expressed by a host gram negative
bacterial cell and the signal is then cleaved properly by the host,
the mature protein without an appended methionine moiety is secreted
20 into the periplasmic space of the host, i.e., the space between the
inner, or cytoplasmic, membrane and the outer membrane of the host.
Also known are host-vector systems in which the signal protein and

at least an amino terminal portion of the mature protein ordinarily associated with the signal is expressed and processed while linked to a heterologous protein, thereby resulting in the secretion of a fusion protein.

5

Secretion of mature eukaryotic protein into the periplasm of gram negative bacteria such as *E. coli* has been an objective of the art for a number of years. Periplasmic secretion is a desirable objective because the product is thereby compartmentalized between the inner and outer cell membranes of the culture cells and not exposed to the rigors of the extracellular medium. Exposure to these rigors, e.g., dilution, unfavorable salts or pH, oxidation, foaming, mechanical shearing and proteases, has handicapped the commercialization of nonperiplasmic secretion systems such as those using *bacillus* or yeast. Also, periplasmic compartmentalization simplifies recovery and purification of the desired mature eukaryotic protein.

10

15


20

25

30


35

Heretofore the vector constructions employed for periplasmic secretion in gram negative bacteria have, to applicants' knowledge, all entailed the use either of complete eukaryotic signals or of partial hybrids. Constructions which encode two typical partial hybrids are schematically shown below, with the secretion cleavage sites generally encountered being designated with an arrow.



Constructions like the partial bacterial preprotein-mature

eukaryotic protein fusions shown in schematic A result in the secretion of fusions of the prokaryotic and eukaryotic proteins. It is inconvenient and sometimes impossible to remove the extraneous amino terminal amino acids encoded by the prokaryotic DNA. On the other hand, constructions like those of schematic B, result in the secretion of mature protein but yields of secreted mature eukaryotic protein are less than desired. It would be useful to construct hybrid vectors as described below which could be expressed as direct hybrids of the prokaryotic signal and mature eukaryotic protein, processed by hosts and secreted into the periplasm. Such a vector is shown below.



J. Kadonaga et al., op cit, prepared a vector of the direct hybrid type in which the beta lactamase signal was linked directly to DNA for mature chicken triose phosphate isomerase. However, the isomerase was apparently neither secreted nor processed but resided as a hybrid protein both free in the cytoplasm and attached to the cytoplasmic side of the inner membrane. These authors concluded that the amino acid sequence of at least the early part of a mature secreted bacterial protein is critical to secretion across the inner membrane of E. coli.

The reasons for the relative difficulty previously encountered in obtaining the secretion of the product of direct hybrids are unknown. However, applicants speculate that while secretion and processing machinery are conserved in bacteria (so that eukaryotic preproteins have been processed in several cases), or the machinery is somewhat flexible (as shown in processing of schematic A-type fusions), a particularly difficult obstacle to secretion would appear to be posed by constructions in which such

bacteria must process the expressed product at a completely artificial cleavage site, i.e., a site which is neither a prokaryotic nor eukaryotic site for about from 1 to 3 residues on either side of the point at which hydrolysis occurs. Contrary to
5 this expectation, and the prior failures and skepticism of those skilled in the art, applicants have found that periplasmic bacteria indeed can process direct fusions of prokaryotic signals with mature eukaryotic proteins, and can do so with secreted mature protein yields higher than those obtained by applicants with eukaryotic
10 preproteins. Particularly satisfactory results have been obtained in secreting mammalian growth hormones.

Mammalian growth hormone is a normal product of the pituitary gland. Mammalian growth hormones are now known to exhibit
15 a degree of species cross-specificity, a function of similar amino acid sequence and conformation. Human growth hormone (hGH) consists of 191 amino acids and has a molecular weight of about 21,500. hGH is in clinical use for the treatment of hypopituitary dwarfism. It also has been proposed to be effective in the treatment of burns, wound healing, dystrophy, bone knitting, diffuse gastric bleeding
20 and pseudoarthrosis.

Recently, hGH has been synthesized in recombinant host cells. See, for example, U.S. 4,342,832. hGH is not significantly
25 degraded by bacterial cells and can be produced directly if the gene for its direct expression, including the appropriately placed start codon, is linked to a suitable promoter. Because prokaryotes frequently do not remove the amino-terminal methionine from the resulting protein, expression of heterologous hGH DNA under control
30 of a bacterial promoter as shown in U.S. Patent 4,342,832 yields hGH having methionine as its first amino acid. The reason for this is that the DNA ATG codon (start codon) is ultimately expressed as methionine. Results to date, for example, with production of hGH in E. coli, have shown that the host cell has only a limited
35 intracellular ability to cleave methionine from hGH and only limited

techniques presently exist to do so in vitro.

E.P.O. Publication Number 127305 provides for the synthesis and secretion of mature hGH in prokaryotic hosts by transforming such hosts with prehGH, i.e., with hGH having its normal eukaryotic signal sequence. Host cells were able to express prehGH, to recognize the eukaryotic signal and to process the preprotein properly. Mature hGH was then recovered from the periplasm, but yields were not as high as desired.

10

One currently used technique for recovery of periplasmic protein is called spheroplasting (H. Neu et al., 1964, "Biochem. Biophys. Res. Comm." 17: 215). This process entails the use of lysozyme to lyse the bacterial wall. It is not attractive particularly for large scale recovery of therapeutic proteins because it entails the addition of another contaminant protein to the periplasmic extract and the spheroplasts are mechanically and osmotically fragile. Further, lysozyme is relatively costly.

20

Another method is called osmotic shock (H. Neu et al., 1965, "J. Biol. Chem." 240(9): 3685-3692). This is disadvantageous principally because it requires two steps, first treatment of viable cells with a solution of high tonicity and second with a cold water wash of low tonicity to release the periplasmic proteins.

25

These methods have been practiced on viable cells. The use of viable cells is undesirable because their proteolytic enzymes are fully active. When applicants attempted to recover secreted hGH from a viable culture of E. coli, a proteolytic clip of unknown origin removed the amino terminal phenylalanine from about 10 to 20 percent of the hGH.

30

Accordingly, it is desirable to provide improved methods to recover periplasmic proteins. Such improved methods would minimize proteolytic degradation by proteases during recovery,

35

and in general would be sufficiently delicate to minimize contamination of periplasmic protein by intracellular proteins. They also would permit the recovery of large proportions of periplasmic protein by manipulative steps more amenable to commercial, large scale use than currently available procedures, and would not entail the use of contaminating proteinaceous reagents.

It is also desirable to express and secrete high periplasmic amounts of mature eukaryotic protein in bacterial hosts.

It is further desirable to obtain periplasmic mature human growth hormone in elevated amounts.

It is also desirable to provide prokaryotic signal polypeptides capable of facilitating the expression and secretion of eukaryotic proteins.

SUMMARY

Mature eukaryotic protein is expressed and secreted in the periplasmic space of a host organism by a method comprising

- (a) constructing a vector for expressing a secretable direct hybrid, which vector contains DNA encoding a prokaryotic secretion signal sequence linked at its 3' end to the 5' end of DNA encoding the mature protein;
- (b) transforming the prokaryotic host organism with the vector of step (a);
- (c) culturing the transformed host of step (b); and
- (d) allowing mature protein to collect in the periplasm of the host.

A DNA sequence is provided which encodes a periplasmic bacterial secretion signal sequence linked at its 3' end to the 5' end of DNA encoding a mature eukaryotic protein other than chicken triose phosphate isomerase. The DNA encoding E. coli enterotoxin

signals are particularly useful in this regard. This signal DNA is characterized by not being linked (a) at its 3' end to the 5' end of DNA encoding mature enterotoxin or (b) at its 5' end to the 3' end of the enterotoxin promoter. It is conveniently employed as a cassette in the construction of enterotoxin signal-containing vectors. A preferred enterotoxin is STII.

The STII Shine-Dalgarno (S.D.) sequence is a particularly powerful ribosome binding site which contributes to yield improvement. It ordinarily is linked to prokaryotic promoters such as the tryptophan (trp) or bacterial alkaline phosphatase (AP) promoters, and could be employed with any promoter system.

New prokaryotic cell cultures are produced upon transformation and culture of host cells using the above method. These cultures comprise (a) mature eukaryotic protein and (b) a direct hybrid fusion protein of the mature eukaryotic protein with a prokaryotic secretion signal sequence. Ordinarily, greater than about 25 percent, generally up to about 90 percent, of the total weight of mature and fusion protein is mature protein located in the periplasm of the cell.

The method herein generally comprises obtaining viable or killed cells which have been transformed to secrete a heterologous or eukaryotic protein, causing the outer membrane of the cells to become permeable for passage of the protein out through the membrane as for example by freezing and thawing, and separating the periplasmic proteins, including secreted eukaryotic protein, from the remainder of the cells. It also is advantageous to culture the cell under phosphate-limiting conditions to engender changes in the cell membranes which enhance recovery of the periplasmic protein.

A novel killing method is provided wherein transformed cells are contacted with an alkanol and heated. These cells then are treated by a cold shock method comprising freezing and thawing

which enables recovery of periplasmic proteins.

5 These methods are employed to particular advantage in recovering hGH from gram negative organisms which express and process a direct hybrid fusion of the E. coli STII enterotoxin signal with mature hGH.

Brief Description of the Drawings

10 Fig. 1 discloses the STII gene, including its translated and untranslated regions. The principal portion of its S.D. sequence is overlined at nucleotides 155-161. The imputed amino acid sequence for the STII signal is located at residues -23 to -1 and for the mature STII enterotoxin at residues 1-48. Fig. 1 also
15 discloses the processing site for STII (designated "cleavage site") and various restriction enzyme sites. The asterisk designates the likely mRNA synthesis initiation site assuming that the STII promoter includes the overlined structures at position 84 - 89 and 108 - 114.

20 Figs. 2a - 2d disclose the construction of a vector (ptrp-STII-hGH) encoding a secretable STII-hGH fusion protein under the control of the trp promoter and containing an STII S.D. sequence.

25 Fig. 3 is a detail of the plasmid trp-STII-hGH.

 Fig. 3a is the nucleotide sequence of the trp promoter region, STII signal and the hGH gene in ptrp-STII-hGH.

30 Figs. 4a-4c disclose the construction of the vectors pAP-1 and pAP-STII-hGH encoding secretable AP-hGH and STII-hGH fusion proteins under the control of the AP promoter, the vector encoding the latter containing an STII S.D. sequence.

35 Fig. 5 is the nucleotide sequence of the AP promoter

region, STII signal and the hGH gene in pAP-STII-hGH.

Fig. 6 is the nucleotide sequence of the AP promoter region, the AP signal and the hGH gene in pAP-1.

5

Detailed Description

A heterologous protein is a protein not ordinarily secreted by the bacterial cell. While such a protein may be an ordinarily
10 intracellular protein of the transformed cell that has been engineered for secretion, or it may be a protein encoded by DNA from another microbe, ordinarily it is a eukaryotic protein, a fragment thereof or a fusion thereof with a prokaryotic protein or fragment. Preferably the periplasmic protein is a mature eukaryotic protein
15 such as a hormone, e.g., hGH, an interferon or a lymphokine.

The cells to be treated herein may be obtained from cultures of transformed bacteria grown in conventional media or media tailored to the vectors or mutant host transformants used to
20 secrete the heterologous protein.

Applicants have demonstrated the secretion of direct hybrid fusions of a prokaryotic signal and desired eukaryotic protein, notwithstanding the complexity of the host vector systems at both
25 the level of preprotein synthesis and secretion. Plasmids were constructed in which the trp or AP promoters were employed with various directly linked prokaryotic signal and eukaryotic protein sequences. Suitable hosts were transformed with each of these plasmids and the amount and distribution of product between the
30 periplasm and cytoplasm determined. These experiments demonstrated that mature eukaryotic proteins are secreted and correctly processed into the periplasmic space of organisms from direct hybrid fusion proteins. The following table shows the results of successful experiments. The results obtained by using the normal hGH
35 eukaryotic signal are shown for comparison.

Table 1

Effect of Promoters and Signal Peptides on
Expression and Secretion of Eukaryotic Proteins

5	Promoter	Signal	Gene	Host	Locations/Levels ³	Processing ⁴	Media
	trp	STII	hGH	294 or W3110 ⁸	90 percent periplasmic; 1 gram	correct	defined or LB
10	AP	STII	hGH	W3110	50 percent periplasmic; 0.5 gram	correct	defined-pi ¹
	AP	AP	hGH	294 ²	90 percent periplasmic; 0.1 gram	correct	LB-pi
15	trp	hGH	hGH	294 or W3110	90 percent periplasmic; 50 mg	correct	defined/LB
	trp	STII	hLIF-A ⁶	294	50 percent periplasmic; 1.9 mg	correct	LB
20	trp	STII	mIgG-K ⁷	294	60 percent periplasmic; ND	ND ⁵	LB

1 inorganic phosphate depleted medium

2 E. coli ATCC 31446

3 Variation is typically encountered among experiments. Relevant parameters include culture density, the time at which secreted protein is recovered, and other variables. The total amount of mature and fused eukaryotic protein, as well as the periplasmic percentage, must be considered approximate. The levels are reported as grams/50 equivalent culture OD units at 550 nm/liter. Cultures were grown in 10 or 20 ml fermentations in shake flasks.

4 Correct processing means that the secreted protein exhibited the same amino terminus as is found when the protein is

isolated from natural sources.

5 ND means not done.

6 human leukocyte interferon - A

7 The light chain of a murine monoclonal anti-CEA immunoglobulin.

5 8 E. coli ATCC 27325

Applicants' initial attempts to secrete some mature eukaryotic proteins using prokaryotic signals in the above structural format did not result in synthesis of protein in some cases, and in others expression was not accompanied by secretion. Cultures transformed with vectors for the murine immunoglobulin heavy chain (using the STII signal), human tissue plasminogen activator (using the AP promoter and signal) or a bovine prorennin (using the trp promoter and the STII signal in E. coli hosts), or hGH (using the Pseudomonas aeruginosa enterotoxin A signal) synthesized very low or undetectable quantities of either the preprotein or secreted mature protein. Other transformed cultures failed to process STII signal fusions with bovine gamma interferon, prorelaxin, interleukin-2 or bovine prorennin. These results were obtained in limited and preliminary experiments.

It is clear from this work that direct hybrid fusions of prokaryotic signals with mature eukaryotic proteins are recognized by bacterial cells, i.e., processed and transported into the periplasm. Given that knowledge, the skilled artisan must nonetheless exert diligence in identifying functional constructions.

This effort should be directed first at screening vectors encoding direct hybrid fusions with signals obtained from a variety of periplasmic bacterial proteins, e.g. enzymes or enterotoxins. If the secretion of mature eukaryotic protein is not obtained upon the transformation and culture of E. coli with such constructions then other genera of gram negative bacteria should be screened for the ability to secrete the mature protein. Lastly, the signal peptide may be mutated in order to enhance or modify its processing

characteristics.

The method herein is facilitated by the ability of gram negative bacteria to recognize direct fusions with the STII enterotoxin signal peptide. Furthermore, it is based on the additional discovery that elevated yields are obtained by use of the STII S.D. sequence.

Partial amino acid sequences for hGH and STII enterotoxin preproteins are shown below with the starting amino acid for each mature protein being underlined.

hGH ...leu gln glu gly ser ala phe pro ala met ser leu...

STII ...ala thr asn ala tyr ala ser thr gln ser asn lys...

As can be seen, virtually no homology whatever exists between these two sequences in the vicinity of their signal cleavage sites. Thus it was surprising that the host cells were able to recognize the STII-hGH hybrid junction and process the STII-hGH preprotein correctly and secrete hGH.

The prokaryotic signal sequence to be used herein is the signal sequence from any bacterial secreted or cell membrane protein, or mutation thereof. Examples of suitable signals are those associated with hydrolases, phosphatases, proteases, antibiotic resistance enzymes, e.g. beta lactamase, binding proteins such as MalE (maltose binding protein) and enterotoxins. The beta lactamase signal is not preferred. The preferred embodiments are found among the heat stable (ST) and heat labile (LT) enterotoxins of E. coli. Of the ST enterotoxins, STII is most preferred.

According to Picken et al., op cit, the STII signal polypeptide was either the amino acid sequence NH₂-met lys lys asn ile ala phe leu leu ala ser met phe val phe ser ile ala thr asn ala, or this sequence with an additional carboxyl-terminal tyr ala. In

fact, E. coli cleaves the signal after tyr ala. Thus, the STII signal DNA which is used in the vectors further described herein will encode the tyr ala alternative.

5 The prokaryotic signal may be mutated in order to increase the proportion of eukaryotic protein that is secreted. Generally, mutations in codons encoding amino acid positions outside of the hydrophobic core of the signal, e.g., residues -1, -2 or -3, are more likely to exert a significant effect on signal cleavage. The
10 mutated DNA will express an amino acid at the site of mutation which is different from the wild type signal. Most conveniently a plurality of codons are substituted at a given position, each of which encodes a different amino acid. This is accomplished by methods known in the art. For example see S. Michaelis, op. cit.,
15 as applied to the alkaline phosphatase signal. Each individual construction then is ligated to DNA encoding the mature human protein in an expression vector, the vector used to transform hosts, the transformants cultured and the secretion level determined for each mutant as is more fully described below. Transformants that
20 secrete optimal levels of desired protein are identified and the responsible constructions selected. With respect to the STII signal, it is expected that amino acid substitutions in the hydrophobic region (residues -5 to -17 in Fig. 1) will not adversely affect the signal efficacy so long as the substituted amino acids
25 are uncharged and, preferably, hydrophobic. Also, deletions or insertions of one or two like residues in this region are acceptable. The most sensitive region of the leader is residues -1 and -21 to -22 (Fig. 1). Mutations in these residues, including insertions or deletions generally are deleterious, but occasionally
30 beneficial effects on yield or secretion are obtained. Mutations that are so extensive as to convert the expressed signal to the eukaryotic signal ordinarily associated with the desired protein or other eukaryotic proteins are not prokaryotic signal mutations as defined herein.

35

Mutagenic optimization is particularly desirable upon switching from one host to another while using vectors containing substantially the same signal. The reason for this is that allelic variants in the bacterial enzyme system responsible for cleaving the signal-eukaryotic protein fusion and transporting the mature protein may more readily recognize a suitably modified prokaryotic signal.

In accordance with this invention any eukaryotic protein, mutant or derivative may be secreted if proper gram negative hosts and signals are selected, provided of course that the protein per se is capable of being expressed in gram negative hosts. Such eukaryotic proteins include lymphokines, immunoglobulins and hormones. The eukaryotic proteins used herein ordinarily are mammalian proteins such as those of bovine, porcine and human origin. Particularly advantageous results are obtained with growth hormones such as human growth hormone.

Vectors for transforming hosts to express direct hybrid fusion proteins are made in conventional fashion by methods generally known to those skilled in the art. In such vectors, DNA encoding the prokaryotic signal is directly linked to DNA encoding the desired protein. This means that the signal DNA encoding the amino acid immediately upstream from the normal bacterial cleavage site is linked directly to the DNA encoding the first amino acid of the desired mature eukaryotic protein, without any intervening residual sequences from the mature prokaryotic protein or the normal eukaryotic pre sequence. Such direct linkage is accomplished by known methods such as the M13 deletional mutagenesis procedure described in the examples. Alternately, one may chemically synthesize DNA encoding the signal and cleavage region. This DNA is blunt end ligated, or ligated through a convenient restriction enzyme site, to DNA encoding the remainder of the eukaryotic protein.

DNA encoding the alkaline phosphatase or STII signal is directly linked in either fashion to DNA encoding the desired mature

eukaryotic protein. When the eukaryotic protein is a growth hormone, the signal will be linked to DNA having as its two first 5' codons, codons which encode at least the first two amino-terminal amino acids of hGH, i.e., NH₂-phe pro, and preferably encode the first 15 amino-terminal amino acids of hGH. This sequence ordinarily is part of a DNA sequence encoding growth hormone such as hGH, bovine growth hormone (having the amino-terminal sequence phe pro ala met ser leu) or porcine growth hormone (having the amino-terminal sequence phe pro ala met pro leu) and the allelic variants thereof.

Suitable vectors for use herein are constructed by operably ligating the direct hybrid fusion DNA to replication and translation effecting sequences. Sequences which effect translation of the mRNA include an S.D. sequence present upstream from the prokaryotic signal. Preferably, the S.D. sequence used herein is that of STII, and it is spaced from the prokaryotic signal start codon by the natural intervening sequence (TTTT) found in the STII gene. This construction is obtained most easily by isolating the STII signal complete with its S.D. sequence and normal intervening sequence from a source of the STII gene as is further described below. However, because this portion of the STII gene is only 80 bp long it also is practical to simply synthesize the required sequence by known chemical methods. This is especially preferred if extensive mutagenesis of the signal is contemplated. The construction shown in Fig. 3a contains two S.D. sequences, one upstream S.D. sequence donated by the trp promoter and then the STII S.D. sequence in its normal relationship with the STII signal DNA. We believe that the upstream, non-STII S.D. sequence is not required. Other prokaryotic signal sequences such as the AP signal also may be synthesized by chemical methods as they tend to be less than 100 bp in length.

Transcription of the foregoing S.D.-signal-protein sequence is under the control of a promoter. The promoter is preferably a prokaryotic promoter other than the promoter ordinarily associated

with the selected prokaryotic signal. The preferred embodiment is the AP promoter, although others such as the tac, trp or lactose (D. Goeddel et al., "Nature" 281: 544 [1979]) promoters are satisfactory. While these are the most commonly used, other
 5 microbial promoters have been discovered and utilized, and details concerning their nucleotide sequences have been published, enabling a skilled worker to ligate them functionally with plasmid vectors (Siebenlist et al., 1980, "Cell" 20: 269). The promoter does not
 10 appear to affect the proportion of eukaryotic protein that is secreted. However, it is desirable to screen combinations of promoters and signal sequences for optimal expression since both elements interact in affecting expression levels. For example, compare the results in Table 1 when the STII signal is substituted for the AP signal in combination with the AP promoter.

15 The promoter-S.D.-signal sequences are present in vectors containing replicon sequences compatible with the host cells. The vectors are generally plasmids rather than phage. They contain a replication site as well as phenotypic marking sequences to
 20 facilitate identification of transformed cells. For example, E. coli is typically transformed with a derivative of pBR322, (Bolivar et al., "Gene" 2: 95 [1977]), a plasmid containing genes for ampicillin and tetracycline resistance.

25 When a DNA sequence is "operably ligated or linked" to another it means that the DNA sequence in question exerts an influence on other DNA sequences. This generally means that the first DNA controls either the transcription or ultimately the translation of the DNA to which it is operably ligated, or affects
 30 the processing of the translated protein. For example, a promoter is operably ligated to DNA encoding a preprotein when it affects the rate of translation of the preprotein mRNA. A signal polypeptide is operably ligated to DNA encoding a desired protein when it is placed in reading frame with and ligated directly to the DNA encoding the
 35 protein. The term "ligated" in reference to a composition should

not be inferred to mean that the composition is only defined in terms of its possible manufacture by ligation. On the contrary, operably ligated elements in a plasmid can be synthesized chemically as a unitary entity.

5

The host cells that are transformed with the foregoing vectors are bacteria (a).having a periplasmic space between two cell membranes, (b) in which the vector replicates and (c) in which the preprotein is both expressed and processed. The hosts are generally
10 gram negative organisms, particularly Enterobacteriaceae or Pseudomonas and mutants thereof. Host vector systems (hosts transformed with vectors) are preferred in which the promoter controlling expression of the hybrid fusion is constitutively activated or derepressed. A constitutive mutant is one that is
15 capable of secreting a given protein, which here is the promoted direct hybrid fusion and, in some cases; the normally promoted protein, without induction or other changes in culture conditions calculated to derepress or activate the promoter. Either the host cell or the promoter, or both, may be mutated in order for the
20 host-vector system to be constitutively promoted. The promoter used in the vector may be mutated so that it is no longer capable of being repressed by a repressor protein. Such mutations are known. Alternatively, the host cells are mutated to become constitutive for proteins under the control of a wild-type or unmutated promoter.
25 Such hosts are conveniently prepared by transduction from publically available strains containing the mutant alleles. Preferably, host cells transformed with AP promoter-bearing vectors carry a *phoT* or *phoR* mutant allele. The former is a disabling mutant believed to be in the gene encoding a phosphate ion transport protein. The *phoR*
30 mutant is a disabling mutant in the gene encoding a repressor protein. These mutant alleles are widely known and available in the art and may be transferred into hosts by known techniques. Surprisingly, the constitutive hosts processed a greater percentage of the expressed product than the wild type hosts which were induced
35 by phosphate depletion.

The host cells may, but need not constitutively express the host protein normally promoted by the promoter used to control transcription of DNA for the direct hybrid fusion. For example, either an E. coli phoA deletion mutant, which fails to express active AP, or an AP-synthesizing cell may be used as host; the active secretion of AP by the cells does not necessarily interfere with secretion of the eukaryotic protein. Ordinarily, the host bacterium will be the same species from which the signal was obtained.

While any culture medium ordinarily used for the host cells is satisfactory for the transformants, the composition of host culture medium exerts a strong effect on the secretion of eukaryotic protein by wild type hosts (rather than strain W3110 phoA, phoT or phoA, phoR). Media containing yeast extract results in improved secretion when compared to tryptone (a tryptic digest of casein) or a synthetic mixture of 19 amino acids. It appears that one or more components of yeast extract helps to activate secretion.

In the preferred embodiment the cells are to be grown under phosphate limiting conditions prior to harvest of the culture. This is the case whether or not the organism is transformed with a vector encoding a eukaryotic protein under the control of a promoter for a phosphate processing protein, or whether the cell is defective in transporting or catabolizing phosphate nutrients. Surprisingly, the use of a phosphate-limiting culture medium prior to cell harvest during the late stages of fermentation greatly improves the mechanical characteristics of transformed gram negative organisms. These characteristics enhance the efficacy of the cold shock extraction method described infra. The medium is made phosphate limiting, for example, by either precipitating the phosphate from the medium, by introducing phosphate to the culture at a limiting feed rate, or by providing an initial supply of phosphate that will be inadequate to support optimal growth of the culture beyond a certain predetermined density. The initial supply will be

sufficient to support optimal cell growth during early stages of the fermentation, for example log phase growth or to an OD₅₅₀ of about 45. The amount of phosphate will be tailored to the other nutrients and to the strain of organism used in the culture. Ordinarily,
5 about 2.5 g/l of potassium/sodium phosphate salts are employed in media for use with E. coli W3110 (ATCC 27325), but larger amounts (about 4.0 g/l) are used with cells having phosphate metabolism defects such as the phoT mutant. This is in contrast with
10 nonlimiting quantities of phosphate (about 9.0 g/l). The amount of phosphate ion in the limiting culture medium at the point the culture becomes limiting is less than about 1 mM. Typically the cells are cultured under these limiting conditions for at least about 1 hour prior to harvest.

15 Preferably the cells are permitted to accumulate periplasmic heterologous protein to a maximum level, usually during a growth stage following logarithmic growth, prior to initiation of the treatment provided herein. The cells should be killed as soon as this point is reached or shortly thereafter. The term "killed"
20 means that the cells at least are unable to replicate. It is likely, however, that treatment with alkanol and heat as is further described infra interdicts or destroys metabolic functions not directly associated with replication. However, other than
25 elimination of a deleterious proteolytic activity of E. coli towards periplasmic hGH the impacted metabolic functions remain unknown. The killing procedure should not rupture, lyse or weaken the inner cell membrane of the host organism.

30 Cells that have reached the desired point of growth are preferably killed by immediately contacting them with an alkanol and heating. The alkanol should not be an alkanol which is lytic for cell membranes, e.g. 1-octanol. Generally, suitable alkanols include lower (C₂ to C₄) monohydroxy alkanols such as 1-butanol or ethanol, preferably 1-butanol. The alcohol should be contacted
35 with the cells by adding the alkanol to the fermentation culture

while continuously mixing.

The amount of alcohol which is added will be such as to bring the culture to an alkanol concentration of about from 0.5 percent to 10 percent vol/vol, and preferably about to 1.5 percent vol/vol for 1-butanol. Butanol is preferred because as little as about 0.5 percent can be used; larger proportions are needed for equivalent inactivation when using a propanol or ethanol.

Contemporaneous with or after the addition of alkanol to the cell culture, the temperature of the culture is increased to and held at a level sufficient in conjunction with alkanol to kill the cells. Ordinarily this will be about from 0.5 to 20 minutes at a temperature of about from 55°C to 35°C, the higher temperatures being employed for the lesser periods. The alkanol enables the heating to be conducted at a lower temperature than would otherwise be required, an advantage in preserving the activity of proteins to be recovered.

Cell killing is not critical. Since it is useful in preventing or retarding product degradation it may be dispensed with if the cells can be processed quickly and regulatory requirements for handling recombinant cells can be otherwise complied with. However, we have found that killing the cells approximately doubles the product protein recovery without reducing the purity of the product protein in the recovered supernatants.

After the cells are cultured and/or killed, periplasmic protein is recovered. This generally entails forming a paste of the cells, freezing the cells, thawing the cells, suspending them in buffer, and separating the periplasmic proteins from cell debris, e.g. by low speed centrifugation or filtration. The periplasmic proteins, including secreted eukaryotic proteins, are located in the supernatant. Eukaryotic periplasmic proteins may be obtained in higher specific activity, i.e. purity, than is attained with osmotic

shock methods, and treatment with a hypertonic agent such as 20 percent sucrose is not required, but it should be understood that any method for causing the outer membrane of the cell to become permeable to the periplasmic protein can be used with killed cells.

5

The cell paste to be frozen is produced by centrifuging or filtering the cell culture and recovering the cell mass. This paste typically contains residual quantities of the fermented culture medium, e.g. LB (Luria Broth) medium; it is unnecessary to wash the cells with a freezing menstruum prior to the subsequent steps. It is not critical that a cell paste be formed as the cold shock extraction method herein is largely independent of cell density. However, the economics of freezing and thawing large volumes of material are such that small paste volumes are preferred.

15

The cell freezing should be as soon as possible. Generally the paste at room temperature is placed in a freezer at -20°C until frozen, and then stored at -80°C until further processing is required.

20

The frozen paste is thawed and diluted into several volumes of water or aqueous buffer, preferably about 3 or greater volumes of 10 mM tris-HCl buffer at pH8. This buffer is hypotonic to the intracellular contents of the host organisms. The following steps are performed at about 4°C . The dilutions generally should be about 3 volumes of buffer, although the identity, concentration, and pH of buffer will vary depending upon the periplasmic protein to be recovered.

25

30

The cells are thoroughly suspended in the buffer. This step is facilitated by suspending the cells in the buffer by use of a homogenizer set at a speed at which no substantial lysis of the cells occurs.

35

The suspended cells are gently stirred for about from 10 to

60 minutes, ordinarily about 30 minutes. Then the cell debris and cells (containing cytoplasmic proteins) are removed by centrifugation, typically 12,000 x g for 30 minutes, or by filtration. The supernatant contains the periplasmic proteins, solubilized outer membrane proteins, residual culture medium and extracellular proteins, and a small proportion of soluble intracellular proteins. The desired eukaryotic protein may be purified from the supernatant in accord with further procedures as desired.

The freeze-thaw extraction method described above offers considerable advantages in terms of yield and, surprisingly, purity of the desired periplasmic protein when compared to extraction of either fresh killed or unkilld transformants with buffer alone. Approximately 5 to 26 times as much hGH is recovered from frozen unkilld cells than from unfrozen, unkilld buffer-extracted cells. The supernatants from frozen killed cells were about 19 percent hGH by weight of total protein, but from fresh killed cells only about 16 percent hGH.

The foregoing method is applied in the following Examples to the recovery of hGH from E. coli transformed with a vector which expresses mature hGH as a direct hybrid fusion with the E. coli heat stable enterotoxin STII signal peptide. However, it will be appreciated that the recovery method herein is applicable to the separation of periplasmic proteins from transformed bacterial cells in general, e.g. those disclosed in U.S. patents 4,411,994 and 4,375,514; K. Talmadge et al., op cit (both citations); O. Zemel-Dreassen et al., op cit and G. Gray et al., op cit.

In order to simplify the Examples certain frequently occurring and well-known methods employed in recombinant constructions will be referenced by shorthand phrases or designations.

Plasmids are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids or sources of DNA herein are commercially available, are publically available on an unrestricted basis, or can be constructed from
5 available plasmids or polynucleotides in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan since the plasmids generally only function as replication vehicles for the preprotein and its control sequences, or for elements thereof in intermediate
10 constructions.

"Digestion" of DNA refers to catalytic cleavage of the DNA with an enzyme that acts only at certain locations in the DNA. Such enzymes are called restriction enzymes, and the sites for which each
15 is specific is called a restriction site. "Partial" digestion refers to incomplete digestion by a restriction enzyme, i.e., conditions are chosen that result in cleavage of some but not all of the sites for a given restriction endonuclease in a DNA substrate.

20 The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements as established by the enzyme suppliers were used. Restriction enzymes commonly are designated by abbreviations composed of a capital letter followed by other letters and then,
25 generally, a number representing the microorganism from which each restriction enzyme originally was obtained. In general, about 1 μ g of plasmid or DNA fragment is used with about 1 unit of enzyme in about 20 μ l of buffer solution. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the
30 manufacturer. Incubation times of about 1 hour at 37°C are ordinarily used, but may vary in accordance with the supplier's instructions. After incubation, protein is removed by extraction with phenol and chloroform, and the digested nucleic acid is recovered from the aqueous fraction by precipitation with ethanol.
35 Digestion with a restriction enzyme infrequently is followed with

bacterial alkaline phosphatase hydrolysis of the terminal 5' phosphates to prevent the two restriction cleaved ends of a DNA fragment from "circularizing" or forming a closed loop upon ligation (described below) that would impede insertion of another DNA fragment at the restriction site. Unless otherwise stated, digestion of plasmids is not followed by 5' terminal dephosphorylation. Procedures and reagents for dephosphorylation are conventional (T. Maniatis et al., 1982, Molecular Cloning pp. 133-134).

"Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide gel electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the DNA from the gel, generally by electroelution. This procedure is known generally. For example, see R. Lawn et al., 1981, "Nucleic Acids Res." 9: 6103-6114, and D. Goeddel et al., 1980, "Nucleic Acids Res." 8: 4057.

"Southern Analysis" is a method by which the presence of DNA sequences in a digest or DNA-containing composition is confirmed by hybridization to a known, labelled oligonucleotide or DNA fragment. For the purposes herein, unless otherwise provided, Southern analysis shall mean separation of digests on 1 percent agarose, denaturation and transfer to nitrocellulose by the method of E. Southern, 1975, "J. Mol. Biol." 98: 503-517, and hybridization as described by T. Maniatis et al., 1978, "Cell" 15: 687-701.

"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or chromosomal integrant. Unless otherwise provided, the method used herein for transformation of E. coli is the CaCl_2 method of Mandel et al., 1970, "J. Mol. Biol." 53: 154.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (T. Maniatis et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units of T4 DNA ligase ("ligase") per 0.5 µg of approximately equimolar amounts of the DNA fragments to be ligated.

"Preparation" of DNA from transformants means isolating plasmid DNA from microbial culture. Unless otherwise provided, the alkaline/SDS method of Maniatis et al., Id. p. 90., may be used.

"Oligonucleotides" are short length single or double stranded polydeoxynucleotides which are chemically synthesized by known methods and then purified on polyacrylamide gels.

All literature citations are expressly incorporated by reference.

Example 1

20

Construction of a Plasmid Encoding for the E. coli Heat-Stable Enterotoxin (STII) Gene Signal Peptide Sequence.

The following construction is illustrated in Fig. 2a. The plasmid pWM501 (Picken et al., op cit) contains the heat-stable enterotoxin (STII) gene. A portion of the DNA which encodes the STII gene was recovered from pWM501 1 (stippled region of Fig. 2a) using the following steps. pWM501 was digested with RsaI and the 550 bp DNA fragment 2 was isolated. This gene fragment was ligated to the phage M13mp8 (J. Messing et al. in the Third Cleveland Symposium on Macromolecules: Recombinant DNA, Ed. A. Walton, Elsevier, Amsterdam (1981) pp 143-153) that had been previously digested with SmaI. The ligated DNA was used to transform E. coli JM101, a commercially available strain for use with the M13 phage. Clear plaques were recovered. The double stranded M13mp8 STII Rsa

derivative 3 was isolated from an E. coli JM101 infected with this phage using standard procedures (J. Messing et al. op cit). By the use of the M13mp8 subcloning procedure just described the approximately 550 base pair fragment 2 containing the STII leader gene is now bounded by a series of different restriction endonuclease sites provided by the phage. The M13mp8 STII Rsa derivative 3 then was digested with EcoRI and Pst I and a DNA fragment 4 slightly larger than fragment 2 was isolated.

EcoRI-PstI fragment 4 was subcloned into pBR322. This was accomplished by digesting pBR322 with EcoRI and PstI and isolating the vector 5. The isolated vector 5 was ligated to the EcoRI-PstI DNA fragment 4. This DNA mixture was used to transform E. coli 294 and tetracycline resistant colonies selected. A plasmid 6 was isolated from a resistant E. coli colony and designated pSTII partial.

Example 2

Construction of a Plasmid encoding the STII Signal Peptide Under the Control of the Trp Promoter.

This construction method is shown in Fig. 2b. pSTII partial from Example 1 was digested with MnlI and BamHI and a 180 bp fragment 7 containing the STII S.D. sequence, the STII signal sequence, and the first 30 codons of the mature STII gene was isolated. DNA fragment 7 was ligated to a plasmid containing the trp promoter. One such plasmid pGH207-1, 8, has been described previously (H. de Boer et al., 1982, in: Promoters: Structure and Function, Eds. R. Rodreguez et al. Chamberlin, Praeger Pub., New York, NY, pp 462-481). A derivative of this plasmid, pGH207-1*, wherein the EcoRI site 5' to the trp promotor had been converted to EcoRI* by filling in with DNA polymerase I (DNA pol I) and joining the blunt ends by ligation (S. Cabilly et al., 1984, "Proc. Natl. Acad. Sci. USA" 81: 3273-3277) was used in this example. The trp

promoter-containing plasmid was digested with XbaI and treated with DNA pol I and all four dNTPs to fill in the protruding sequence. The DNA preparation was then digested with BamHI and the vector containing fragment 9 isolated. Vector fragment 9 then was ligated to the 180 bp STII signal-containing DNA fragment 7 isolated above. The ligation mixture was used to transform E. coli 294 to ampicillin resistance. A plasmid designated STII leader 10 was isolated from an ampicillin resistant colony. This plasmid contains the STII signal sequence and a portion of the gene encoding mature STII under the control of the trp promoter. In the following example, the DNA sequence encoding mature hGH was operably ligated downstream from the trp - STII signal sequence.

Example 3

Construction of an Expression and Secretion Plasmid for hGH

Refer to Figs. 2c-2d for a schematic display of this method. STII leader 10 was digested with BglII then treated with DNA pol I and all four NTP's to fill in the protruding end, and then digested with BamHI. The vector-containing fragment 11 was isolated. The plasmid pHGH207-1 from Example 2 was digested with EcoRI, treated with DNA pol I and all four NTP's to fill in the protruding end, and then digested with BamHI. The hGH gene-containing fragment 12 of about 920 bp was isolated from the BamHI digestion. These two fragments were ligated and the DNA mixture used to transform E. coli 294 to tetracycline resistance. A plasmid designated ptrpSTII-HGH-fusion 13 was isolated from the resistant E. coli colonies. This plasmid still contains extraneous nucleotides encoding a portion of the STII mature protein between the STII leader peptide sequence and the hGH structural gene. These nucleotides were deleted using the M13 site specific mutagenesis procedure (J.P. Adelman et al, 1983, "DNA" 2: 183-193).

The gene from ptrpSTII HGH fusion 13 was incorporated into

the single stranded phage M13mp10 (J. Messing *et al.*, *op cit.* and J. Adelman *et al.* *op cit.*). M13 mutagenesis phage and *E. coli* strains are commercially available. Mutagenesis was accomplished first by digesting plasmid 13 with XbaI and BamHI and then recovering fragment 14. M13mp10 was digested with XbaI and BamHI and the phage fragment (not shown) was isolated. Fragment 14 was ligated into the phage fragment and the ligation mixtures used to transform JM101. The transformed culture was plated and incubated. Phage having the fragment 14 insert were identified as clear rather than blue plaques in the *E. coli* chromogenic indicator lawn. Corresponding phage were grown on *E. coli* JM101, and the culture centrifuged. Single stranded phage 15 are present in the supernatant. Single stranded phage 15 DNA was prepared, annealed to the synthetic oligonucleotide primer 5'pCAAATGCCTATGCATTCCCAACTATACC-OH3', primer extended with DNA pol I and the four NTPs to obtain double stranded DNA (one of which strands contained the deletion), treated with T4 ligase, extracted and used to transform *E. coli* JM101 (See J. Adelman *et al.*, *op cit.*). Note that the first 14 nucleotides of the primer are the coding sequence for the 3' end of the STII signal, while the last 14 nucleotides are the coding sequence for the 5' end of the mature hGH gene. Double stranded phage were obtained from the cellular contents of the transformed JM101, transfected into plated *E. coli* JM101, transfer filter impressions taken of the plates and double stranded phage containing the deletion were identified on the filters by Southern analysis with a 5'-32P-labelled obigonucleotide having the DNA sequence of the primer. Double stranded DNA 17 was prepared from the *E. coli* infected with the M13mp10 containing the gene deletion. This DNA was digested with XbaI and BamHI and the DNA fragment 17 isolated. This was ligated in the presence of fragment 18 from similarly digested and isolated pHGH207-1. The ligation was used to transform *E. coli* 294 to tetracycline resistance. Plasmid p-STII-hGH 19 was recovered and its nucleotide sequence determined. A detailed restriction map of this plasmid is shown in figure 3. The DNA sequence of this plasmid in the vicinity of the hGH gene is shown in Fig 3a.

Example 4

Expression and Secretion of hGH

5

HGH was synthesized in shake culture using plasmid 19 from Example 3. E. coli 294 was transformed with plasmid 19 and inoculated into 10-20 ml of LB medium with 5 µg/ml tetracycline in a 50 or 125 ml shake flask. The flask was cultured for 12-24 hours at 37°C without the addition of any further medium, after which the cells were recovered by centrifuging. Total cellular hGH was assayed by radioimmunoassay of sonicated cells. The secreted hGH was recovered through osmotic shock and determined to be mature hGH by SDS-PAGE and N-terminal amino acid terminal sequencing. Amounts recovered were about ten times that which is expressed when using the human hGH signal under control of the trp promoter.

10

15

Example 5

20

Construction of Plasmid pAP-1 Designed to Express and Secrete Human Growth Hormone (hGH) Under the Control of the AP Promoter and Signal Sequence.

25

30

35

This construction is shown in Figs. 4a-4c. A DNA fragment containing a portion of the AP gene was isolated from the plasmid pHI-1 20 [Inouye, H., et al., J. Bacteriol. 146: 668-675 (1981)]. This was done using a series of steps to introduce an EcoRI site 5' to the AP gene and promoter sequence. The plasmid 20 was digested with HpaI and then ligated to a linker molecule containing two EcoRI sites in tandem. After heat inactivation of the ligase enzyme the DNA was digested with EcoRI and a 1200 bp fragment isolated. This DNA fragment was then treated with HpaII and a 464 bp fragment 21 isolated. A plasmid 22 containing cDNA prepared from human growth hormone mRNA was prepared as described by Martial et al., "Science" 205: 602-606 (1979) and Roskem et al., "Nucleic Acids Res." 7:

305-320 (1979) (see also European Publication No. 127305). Plasmid 22 was digested with HpaII and a 461 bp fragment was isolated. The 461 bp fragment was further digested with PstI and a 200 bp fragment 23 containing part of the hGH gene then isolated. DNA fragments 21 and 23 were ligated to a 3609bp DNA fragment isolated from pBR322 that had been previously digested with EcoRI and PstI. This DNA ligation mixture was used to transform E. coli 294 to tetracycline resistance. A plasmid 24, designated pCHGHpps, was recovered from a transformant colony.

10 In plasmid 24 the gene encoding the AP promoter and signal sequence in pCHGHpps was linked to hGH in the same reading frame. However a number of extraneous nucleotides were present between the signal sequence and the beginning of the mature hGH gene. This extraneous nucleotide sequence was deleted by mutagenesis. pCHGHpps was digested with EcoRI and PstI and the 663 bp fragment 25 isolated. Fragment 25 was introduced into M13mp9 previously digested with PstI and EcoRI. This was ligated and used to transform E. coli JM101. Clear plaques were selected and a derivative phage 26, M13mp9-CHGHpps, was identified and isolated. Phage 26 was annealed to the synthetic oligonucleotide primer 5'PCTGTGACAAAAGCCTTCCCAACCATTC-OH3'. The first 14 nucleotides correspond to the sequence of the 3' end of the AP signal peptide and the last 14 correspond to the 5' end of the mature hGH coding sequence. The site-specific deletion mutagenesis was performed as previously described in Example 3 (see also J. Adelman et al. op cit.). Plaques containing the desired deletion were detected by Southern analysis with the 5'-32P-labeled oligonucleotide primer of this Example. Without enrichment for the desired genotype, nine percent of the plaques screened hybridized to the labelled primer. One of the positives, M13mp9-AP-1, 27, was determined by the dideoxy chain termination nucleotide sequencing method to have the expected sequence. The partial hGH gene, now correctly fused to the AP promoter and signal gene, was introduced into pGH207, 28 (H. de Boer et al., op cit.). This was accomplished by digesting pGH207

with PstI and NdeI, and then isolating the 2750 bp fragment.
Another sample of pHGH207 was digested with NdeI and EcoRI and a
2064 bp fragment isolated. The M13mp9-AP-1 phage was digested by
EcoRI and PstI, and the 602bp AP hGH partial gene 29 was isolated.
5 The 2750 and 2064 bp fragments were ligated in a three-part ligation
with fragment 29, and the ligation mixture then used to transform E.
coli 294 to ampicillin resistance. pAP-1 was isolated from a
resistant colony and characterized by restriction enzyme mapping and
nucleotide sequence analysis.

10

Example 6

Construction of a Plasmid (pAP-STII-hGH) to Express and Secrete hGH Under the Control of the AP Promoter

15

ptrp-STII-hGH (from Example 3) was digested with HpaI and
EcoRI and the vector fragment 31 isolated. A 420 bp AP promoter
fragment 32 was isolated from the plasmid pAP-1 after digestion with
EcoRI and partial digestion with RsaI. Fragments 31 and 32 were
20 ligated and used to transform E. coli 294 to ampicillin resistance.
The plasmid pAP-STII-hGH was isolated and characterized by
restriction enzyme mapping and nucleotide sequence analysis. The
nucleotide sequence and translated amino acid sequence of the
AP-STII-hGH construction is shown in figure 5.

25

Example 7

Recovery of hGH from E. coli Containing the Plasmid pAP-STII-hGH.

30

E. coli W3110 and 294 were transformed respectively with
pAP-STII-hGH or pAP-1 and cultured as described in Example 4 except
that the medium used was phosphate depleted. The amounts
synthesized and the distribution of processed and unprocessed hGH
35 were determined as described in Example 4. The results are

described in Table 1. In small volumes ptrp-STII-hGH produces better results, as can be seen from Table 1, but in 10 liter culture volumes the preferred embodiment is the plasmid pAP-STII-hGH since AP promoted cells can grow to higher densities than trp promoted organisms.

Example 8

Large Volume Fermentation and hGH Recovery

10

Eight hours prior to the start of a 10 liter fermentation a 500 ml inoculum culture is grown up. A transformant of E. coli W3110 (tonA, phoA, phoT) (Example 9) containing pAP-STII-hGH is inoculated into a sterile 2 liter flask containing 500 ml of LB medium and tetracycline (0.5 µg/ml). The culture is incubated in a rotary shaker at 37°C for eight hours. A sterile 10 liter fermentation medium is prepared, containing the following ingredients: 26g K₂HPO₄, 13g NaH₂PO₄ 2H₂O, 15g KCl, 50g (NH₄)₂SO₄, 10g Na₃ citrate, 50 ml of 50 percent glucose, 1000 ml of 10 percent NZ-amine YT, 100 ml of 1M MgSO₄, 5 ml of 2.7 percent FeCl₃, 5 ml of trace metals, 1 ml of 5 mg/ml tetracycline, 5 ml of antifoaming agent, and 6.5 liters of H₂O. The starting pH of the medium is titrated to 7.5 by adding H₂SO₄, and the run is begun by seeding the 500 ml inoculum culture into the 10 liter fermenter. Throughout the run the temperature is maintained at 37°C and the culture agitated under aeration. From the outset, the cells are fed glucose (50 percent) at a flow rate of 0.5 ml/min. When the OD 550 is in the range 10-25 the glucose feed rate is manually adjusted to keep the pH at 7.5 and the residual glucose level $\leq 1/4$ percent. When the OD 550 reaches 25, the glucose feed rate is manually adjusted to drive the dO₂ level to 30 percent and thereafter, the glucose feed rate is periodically adjusted to maintain the dO₂ level at 30 percent. Thirty-six hours after the start of fermentation the cells are killed and harvested.

35

5 The glucose feed and aeration are turned off but the agitation rate of 650 rpm is maintained. 1-butanol is added immediately to the fermenter to yield a final concentration of 1.5 percent and steam is immediately injected into the fermenter jacket so that the temperature in the tank rises rapidly to 50°C. When the temperature reaches 50°C, it is held at this temperature for 10 minutes. Then the fermenter is rapidly cooled below 20°C and the cellular contents of the fermenter are harvested by centrifugation. The cell paste is first frozen at -20°C and then transferred to a
10 -80°C freezer.

The cell paste, frozen at -80°C, is thawed overnight at 4°C and all subsequent steps are performed at 4°C. The paste is mixed in 4 volumes of 10mM Tris-HCl, pH=8.0 and suspended in an
15 Ultra-Turrex homogenizer for 30 seconds. The suspension is stirred for 30 minutes and then the cells are removed by centrifugation at 12,000 x g for 30 minutes. The periplasmic proteins contain in the supernatant mature hGH at between 0.5 and 1 gram/liter/100 OD₅₅₀ with about 95 percent of the total hGH (as estimated from
20 immunoblots with peroxidase-coupled anti-hGH) in processed form in the periplasm. About 50-60 percent of the total cellular hGH is recovered in the supernatant. The supernatant contains about 20 percent hGH by weight of protein.

25 Example 9

Construction of a Host Organism W3110 tonA, phoA, phoT

30 The host organism for the fermentation was constructed in several steps using standard techniques involving transductions with phage derived from P1 (J. Miller, Experiments in Molecular Genetics). The phoT and phoA mutations were sequentially cotransduced from E. coli into strain W3110 tonA with the aid of genetically linked antibiotic-resistance transposons. The presence
35 of the phoT mutation, which was introduced first, was recognized

since these transductants form blue colonies on high phosphate,
phosphochromogen-containing plates (5-bromo-4-chloro-3-indoyl-
phosphate). The introduction of the phoA mutation was recognized as
transductants which form white colonies on low phosphate,
5 phosphochromogen plates. This phoT mutant, or a phoR mutant
constructed in similar fashion, when transformed with pAP-STII-hGH,
secretes over 90 percent of the total hGH into the periplasmic space
over the course of the fermentation. In contrast, a
non-constitutive bacterium such as W3110 only secretes about 50
10 percent of the hGH into the periplasm and total expression levels
are somewhat lower in some cases. The presence or absence of the
phoA mutant makes little or no difference in the yield of
heterologous protein. However, since phoA mutants do not secrete
AP, it is not necessary to separate AP in the course of purifying
15 periplasmic hGH from phoA mutants.

20

25

30

35

CLAIMS:

1. DNA encoding a prokaryotic secretion signal sequence, preferably an E. coli signal sequence other than that of
5 beta-lactamase, such as an enterotoxin signal sequence, or an AP signal sequence, operably linked at its 3' end to the 5' end of DNA encoding a mature eukaryotic protein other than chicken triose phosphate isomerase, preferably a mammalian protein such as hGH, bovine growth hormone or
10 porcine growth hormone.
2. A DNA sequence encoding a protein having at least the amino terminal sequence of mature hGH operably linked to a DNA sequence encoding an enterotoxin signal, preferably the
15 STII signal.
3. The composition of claim 1 or claim 2 wherein the DNA is operably ligated into replicable vector containing in 5' to 3' order, a promoter controlling transcription of the
20 DNA, a Shine-Dalgarno sequence, the DNA, and a termination region comprising a stop codon.
4. A method for the periplasmic secretion of a mature eukaryotic protein in the periplasmic space of a host
25 prokaryote, comprising
 - (a) constructing a vector for expressing a secretable direct hybrid, which vector contains DNA encoding a prokaryotic secretion signal sequence linked at its
3' end to the 5' end of DNA encoding the mature
30 eukaryotic protein;
 - (b) transforming a prokaryotic host with the vector of step (a);
 - (c) culturing the transformed host of step (b); and
 - (d) allowing mature protein to collect in the
35 periplasm of the host.

0177343

5. A method comprising

- (a) constructing a vector comprising a DNA sequence encoding a protein having at least the amino terminal sequence of mature hGH operably ligated to a DNA sequence encoding an enterotoxin signal, preferably the STII signal, the DNA being operably linked to the STII Shine-Dalgarno sequence;
- (b) transforming a host cell with the vector;
- (c) culturing the transformed host cell; and
- (d) recovering the protein from the periplasm of the cell.

6. A prokaryotic cell culture comprising (a) a mature eukaryotic protein, such as hGH, and (b) a direct hybrid fusion protein of the mature eukaryotic protein with a prokaryotic secretion signal sequence wherein the mature protein is located in the periplasm of the cell, with preferably greater than about 25 percent of the total weight of mature and fusion protein being mature protein located in cell periplasm.

7. The culture of claim 6 wherein the total weight of mature and fusion protein is greater than about 2 mg/liter, preferably greater than 4 mg/liter, of culture on a culture optical density basis of 1 at 550 nm and greater than about 50 percent, preferably greater than 80 percent, of the mature protein by weight is present in the periplasm.

8. A protein comprising an enterotoxin signal fused at its carboxyl terminus to the amino terminus of a mature eukaryotic protein.

9. A DNA sequence 5'GAGGTGATTTTATG3' flanked by other than the sequences found in the STII gene, preferably at

its 5' end a promoter other than the STII promoter and at its 3' end a DNA sequence encoding a desired protein, preferably a eukaryotic preprotein.

5 10. A DNA sequence comprising DNA encoding an enterotoxin signal peptide free of DNA encoding mature enterotoxin protein or a fragment thereof.

11. A DNA sequence comprising DNA encoding an enterotoxin
10 signal polypeptide free of enterotoxin promoter DNA.

12. A method for recovering protein from the periplasmic space of a bacterial cell, preferably E. coli, transformed to secrete a eukaryotic protein, preferably mature hGH,
15 comprising

- (a) freezing the cell;
- (b) thawing the cell; and
- (c) separating the periplasmic proteins, including the eukaryotic protein, from the remainder of the cells.

20

13. The method of claim 12 wherein the cells are killed before step (a), preferably

- (a) contacting the cell with an alkanol, most preferably wherein the alkanol is mixed with an aqueous
25 suspension of the cell until an alkanol concentration of about from 0.5 to 10 percent by volume is reached; and
- (b) heating the cell, preferably for about from 35°C to 55°C for about from 0.5 to 20 minutes.

30

14. A method of claim 12 wherein the cell is cultured in a phosphate-limiting culture medium prior to freezing the cell, the culture medium preferably containing less than about 1mM of phosphate.

35

15. A method for the recovery of periplasmic proteins, preferably mature hGH, from a bacterial cell, preferably E. coli, comprising

5 (a) killing the cell, preferably by exposing it to an alkanol and heating;

(b) cooling the cell to a temperature lower than about 20°C, preferably to a temperature sufficient to freeze to cell; and

10 (c) separating periplasmic protein from the remainder of the cell;

the cell being preferably not suspended in a hypertonic solution prior to cooling the cell in step (b).

15 16. A method for the recovery of a eukaryotic protein from the periplasmic space of a bacterial cell transformed to secrete the eukaryotic protein, comprising

(a) killing the cell;

20 (b) causing the outer membrane of the cell to become permeable to passage of the protein out of the cell; and

(c) separating the periplasmic proteins, including the eukaryotic protein, from the remainder of the cells.

25 17. A method for recovering protein from the periplasmic space of a bacterial cell transformed to secrete a eukaryotic protein, said cell not being a phoA mutant, comprising

(a) culturing the cell in a phosphate-limiting nutrient medium;

30 (b) causing the outer membrane of the cell to become permeable to permit passage of the protein out of the cell; and

(c) separating the periplasmic proteins, including the eukaryotic protein, from the remainder of the cells;

35 the cell preferably being a mutant not requiring phosphate


starvation to induce a protein controlled by alkaline phosphatase promoter.


- 5 18. A method for the periplasmic secretion of a mature eukaryotic protein from a transformed host-vector system in which the expression of the protein is under the control of a promoter, characterised in that it uses as the host-vector system a constitutive mutant for expression of a protein under the control of the promoter.
- 10 19. The method of claim 18 wherein the promoter is the alkaline phosphatase promoter and the host is a *phoT* or *phoR* mutant.
- 15 20. The method of claim 18 wherein the mutant is selected from: promoter mutants, host mutants, constitutive alkaline phosphatase mutants, and those which disable the activity of a repressor which otherwise represses the promoter.

THE ST II GENE

TAAATACCTACAACGGGTGATTGACACTACACTCATTAACTATACCTGCAAGTAGCATTAAAAATCTTAATAAAGGAGAGC
 1 20 40 60 80
 -35 -10 MnlI S.D.
 TTGGTCACATTTTGTGACTTGACTCATATAAAGCCCACTGGTATAAGTTTTATTGCTTATAGCAATAAGGTTGAGGTG
 100 120 140 160
 -20 -10
 met lys lys asn ile ala phe leu leu ala ser met phe val phe ser ile ala
 ATTTT ATG AAA AAG AAT ATC GCA TTT CTT CTT GCA TCT ATG TTC GTT TTT TCT ATT GCT
 180 200
 -1 cleavage site
 thr asn ala tyr ala SER THR GLN SER ASN LYS LYS ASP LEU CYS GLU HIS TYR ARG GLN
 ACA AAT GCC TAT GCA TCT ACA CAA TCA AAT AAA AAG GAT CTG TGT GAA CAT TAT AGA CAA
 220 240 260
 20 30
 ILE ALA LYS GLU SER CYS LYS LYS GLY PHE LEU GLY VAL ARG ASP GLY THR ALA GLY ALA
 ATA GCC AAG GAA AGT TGT AAA AAA GGT TTT TTA GGG GTT AGA GAT GGT ACT GCT GGA GCA
 280 300 320 RsaI
 40
 CYS PHE GLY ALA GLN ILE MET VAL ALA ALA LYS GLY CYS OC
 TGC TTT GGC GCC CAA ATA ATG GTT GCA GCA AAA GGA TGC TAA TATATTTATCAATAGCATTTCAGCA
 340 360 380 400
 CCATATACACAAAAATAATTTTTCATAAAAAGAACTCTATAAAATAATATTTTTTGTGACAATGTCCTAACGCAAGAGC
 420 440 460 480
 GACATTGTCCATTCTCAGGTAATGATCTGTAAATAGTC
 500 PstI 520

Fig.1.



*Fig. 2a(Cont.)*

4/18




Fig. 2b






Fig.2c








Fig. 3.

← Trp promoter
AATTCATGCTGTG6TGCATGGTGCATGCCAGGGTGCACGGCGCATCTCGACTGCACGGTGCACCAATGCTTCTG6G6TGCAGGCAGCCAAATC66AAGCTGTGGTATG6CTGTGC

AGGTCGTAATCACTGACATAATTCTGTGCTCAAGGCGCACTCCCGTTCTTG6ATAATGTTTTTTTGGCGCGACATCATACG6TTCTTG6CAAATATTCTGAAATGAGCTGTTGACAATT

AATCATCGAACTAGTTAACTAGTACGCAAGTTACAGTAAAGGGTATCTAGAGGTTGAGGTGATTTT
STII S.D.
trp S.D.
met lys lys asn ile ala phe leu leu ala ser met
ATG AAA AAG AAT ATC GCA TTT CTT CTT GCA TCT ATG

-10
phe val phe ser ile ala thr asn ala tyr ala phe pro thr ile pro leu ser arg leu phe asp asn ala met leu arg ala his arg
TTC GTT TTT TCT ATT GCT ACA AAT GCC TAT GCA TTC CCA ACT ATA CCA CTA TCT CGT CTA TTC GAT AAC GCT ATG CTT CGT GCT CAT CGT

20
leu his gln leu ala phe asp thr tyr gln phe glu glu ala tyr ile pro lys glu gln lys tyr ser phe leu gln asn pro gln
CTT CAT CAG CTG GCC TTT GAC ACC TAC CAG GAG TTT GAA GAA GCC TAT ATC CCA AAG GAA CAG AAG TAT TCA TTC CTG CAG AAC CCC CAG

30
thr ser leu cys phe ser glu ser ile pro thr pro ser asn arg glu glu thr gln gln lys ser asn leu glu leu leu arg ile ser
ACC TCC CTC TGT TTC TCA GAG TCT ATT CCG ACA CCC TCC AAC AGG GAG GAA ACA CAA CAG AAA TCC AAC CTA GAG CTG CTC CGC ATC TCC

40
leu leu leu ile gln ser trp leu glu pro val gln phe leu arg ser val phe ala asn ser leu val tyr gly ala ser asp ser asn
CTG CTG CTC ATC CAG TCG TGG CTG GAG CCC GTG CAG TTC CTC AGG AGT GTC TTC GCC AAC AGC CTA GTG TAC GGC GCC TCT GAC AGC AAC

50
val tyr asp leu leu lys asp leu glu glu gly ile gln thr leu met gly arg leu glu asp gly ser pro arg thr gly gln ile phe
GTC TAT GAC CTC CTA AAG GAC CTA GAG GAA GGC ATC CAA ACG CTG ATG GGG AGG CTG GAA GAT GGC AGC CCC CGG ACT GGG CAG ATC TTC

60
lys gln thr tyr ser lys phe asp thr asn ser his asn asp asp ala leu leu lys asn tyr gly leu leu tyr cys phe arg lys asp
AAG CAG ACC TAC AGC AAG TTC GAC ACA AAC TCA CAC AAC GAT GAC GCA CTA CTC AAG AAC TAC GGG CTG CTC TAC TGC TTC AGG AAG GAC

70
met asp lys val glu thr phe leu arg ile val gln cys arg ser val glu gly ser cys gly phe AM
ATG GAC AAG GTC GAG ACA TTC CTG CGC ATC GTG CAG TGC CGC TCT GTG GAG GGC AGC TGT GGC TTC TAG CTGCCCTTAATGCGGTAGTTTATCACAGTT

80
pBR322
SmaI-Blunt HindIII junction

90
STII S-D Seq. GGTGAGGTGATTTT
StII Leader Seq. -23 to -1
Mature HGH Seq. 1-191

100
110
120
130
140
150
160
170

180
190
191

200
210
220
230
240
250
260
270
280
290
300
310
320
330
340
350
360
370
380
390
400
410
420
430
440
450
460
470
480
490
500
510
520
530
540
550
560
570
580
590
600
610
620
630
640
650
660
670
680
690
700
710
720
730
740
750
760
770
780
790
800
810
820
830
840
850
860
870
880
890
900
910
920
930
940
950
960
970
980
990
1000

1010
1020
1030
1040
1050
1060
1070
1080
1090
1100
1110
1120
1130
1140
1150
1160
1170
1180
1190
1200
1210
1220
1230
1240
1250
1260
1270
1280
1290
1300
1310
1320
1330
1340
1350
1360
1370
1380
1390
1400
1410
1420
1430
1440
1450
1460
1470
1480
1490
1500
1510
1520
1530
1540
1550
1560
1570
1580
1590
1600
1610
1620
1630
1640
1650
1660
1670
1680
1690
1700
1710
1720
1730
1740
1750
1760
1770
1780
1790
1800
1810
1820
1830
1840
1850
1860
1870
1880
1890
1900
1910
1920
1930
1940
1950
1960
1970
1980
1990
2000

2010
2020
2030
2040
2050
2060
2070
2080
2090
2100
2110
2120
2130
2140
2150
2160
2170
2180
2190
2200
2210
2220
2230
2240
2250
2260
2270
2280
2290
2300
2310
2320
2330
2340
2350
2360
2370
2380
2390
2400
2410
2420
2430
2440
2450
2460
2470
2480
2490
2500
2510
2520
2530
2540
2550
2560
2570
2580
2590
2600
2610
2620
2630
2640
2650
2660
2670
2680
2690
2700
2710
2720
2730
2740
2750
2760
2770
2780
2790
2800
2810
2820
2830
2840
2850
2860
2870
2880
2890
2900
2910
2920
2930
2940
2950
2960
2970
2980
2990
3000

3010
3020
3030
3040
3050
3060
3070
3080
3090
3100
3110
3120
3130
3140
3150
3160
3170
3180
3190
3200
3210
3220
3230
3240
3250
3260
3270
3280
3290
3300
3310
3320
3330
3340
3350
3360
3370
3380
3390
3400
3410
3420
3430
3440
3450
3460
3470
3480
3490
3500
3510
3520
3530
3540
3550
3560
3570
3580
3590
3600
3610
3620
3630
3640
3650
3660
3670
3680
3690
3700
3710
3720
3730
3740
3750
3760
3770
3780
3790
3800
3810
3820
3830
3840
3850
3860
3870
3880
3890
3900
3910
3920
3930
3940
3950
3960
3970
3980
3990
4000

4010
4020
4030
4040
4050
4060
4070
4080
4090
4100
4110
4120
4130
4140
4150
4160
4170
4180
4190
4200
4210
4220
4230
4240
4250
4260
4270
4280
4290
4300
4310
4320
4330
4340
4350
4360
4370
4380
4390
4400
4410
4420
4430
4440
4450
4460
4470
4480
4490
4500
4510
4520
4530
4540
4550
4560
4570
4580
4590
4600
4610
4620
4630
4640
4650
4660
4670
4680
4690
4700
4710
4720
4730
4740
4750
4760
4770
4780
4790
4800
4810
4820
4830
4840
4850
4860
4870
4880
4890
4900
4910
4920
4930
4940
4950
4960
4970
4980
4990
5000

5010
5020
5030
5040
5050
5060
5070
5080
5090
5100
5110
5120
5130
5140
5150
5160
5170
5180
5190
5200
5210
5220
5230
5240
5250
5260
5270
5280
5290
5300
5310
5320
5330
5340
5350
5360
5370
5380
5390
5400
5410
5420
5430
5440
5450
5460
5470
5480
5490
5500
5510
5520
5530
5540
5550
5560
5570
5580
5590
5600
5610
5620
5630
5640
5650
5660
5670
5680
5690
5700
5710
5720
5730
5740
5750
5760
5770
5780
5790
5800
5810
5820
5830
5840
5850
5860
5870
5880
5890
5900
5910
5920
5930
5940
5950
5960
5970
5980
5990
6000

6010
6020
6030
6040
6050
6060
6070
6080
6090
6100
6110
6120
6130
6140
6150
6160
6170
6180
6190
6200
6210
6220
6230
6240
6250
6260
6270
6280
6290
6300
6310
6320
6330
6340
6350
6360
6370
6380
6390
6400
6410
6420
6430
6440
6450
6460
6470
6480
6490
6500
6510
6520
6530
6540
6550
6560
6570
6580
6590
6600
6610
6620
6630
6640
6650
6660
6670
6680
6690
6700
6710
6720
6730
6740
6750
6760
6770
6780
6790
6800
6810
6820
6830
6840
6850
6860
6870
6880
6890
6900
6910
6920
6930
6940
6950
6960
6970
6980
6990
7000

7010
7020
7030
7040
7050
7060
7070
7080
7090
7100
7110
7120
7130
7140
7150
7160
7170
7180
7190
7200
7210
7220
7230
7240
7250
7260
7270
7280
7290
7300
7310
7320
7330
7340
7350
7360
7370
7380
7390
7400
7410
7420
7430
7440
7450
7460
7470
7480
7490
7500
7510
7520
7530
7540
7550
7560
7570
7580
7590
7600
7610
7620
7630
7640
7650
7660
7670
7680
7690
7700
7710
7720
7730
7740
7750
7760
7770
7780
7790
7800
7810
7820
7830
7840
7850
7860
7870
7880
7890
7900
7910
7920
7930
7940
7950
7960
7970
7980
7990
8000

8010
8020
8030
8040
8050
8060
8070
8080
8090
8100
8110
8120
8130
8140
8150
8160
8170
8180
8190
8200
8210
8220
8230
8240
8250
8260
8270
8280
8290
8300
8310
8320
8330
8340
8350
8360
8370
8380
8390
8400
8410
8420
8430
8440
8450
8460
8470
8480
8490
8500
8510
8520
8530
8540
8550
8560
8570
8580
8590
8600
8610
8620
8630
8640
8650
8660
8670
8680
8690
8700
8710
8720
8730
8740
8750
8760
8770
8780
8790
8800
8810
8820
8830
8840
8850
8860
8870
8880
8890
8900
8910
8920
8930
8940
8950
8960
8970
8980
8990
9000

9010
9020
9030
9040
9050
9060
9070
9080
9090
9100
9110
9120
9130
9140
9150
9160
9170
9180
9190
9200
9210
9220
9230
9240
9250
9260
9270
9280
9290
9300
9310
9320
9330
9340
9350
9360
9370
9380
9390
9400
9410
9420
9430
9440
9450
9460
9470
9480
9490
9500
9510
9520
9530
9540
9550
9560
9570
9580
9590
9600
9610
9620
9630
9640
9650
9660
9670
9680
9690
9700
9710
9720
9730
9740
9750
9760
9770
9780
9790
9800
9810
9820
9830
9840
9850
9860
9870
9880
9890
9900
9910
9920
9930
9940
9950
9960
9970
9980
9990
10000

Fig.3A.






Fig.4a


11/18

0177343

Fig.4a(Cont.)







14/18

0177343




Fig.4c.

GAATTCAACTTCTCCATACTTTGGATAAGGAAATACAGACATGAAAAATCTCATTGCTGAGTTGTTATTTAAGCTTGCC

CAAAAGAAGAGTCGAAAGAACTGTGTGCGCAGGTAGAAGCTTTGGAGATTATCGTCACTGCAATGCTTCGCAATA

TGGCGCAAATGACCAACAGCGGTGATTGATCAGGTAGAGGGGGCTGTACGAGGTAAGCCCGATGCCAGCATTCC

TGACGACGATACGGAGCTGCTGCGCGATTACGTAAGAAGTTATTGAAGCATCTCGTCAGTAAAGTTAATCTTTTC

AACAGCTGTCATAAAGTTGTCACGGCCGAGACTTATAGTCGCTTTGTTTTATTTTTTAATGTAATTTGTAAGTAGTACG

CAAGTTCACGTAAGAAGGTATCTAGAAAGTTGAGGTGATTTT
 trp S.D. STII S.D. -23 -20
 met lys lys asn ile ala phe leu leu
 ATG AAA AAG AAT ATC GCA TTT CTT CTT

ala ser met phe val phe ser ile ala thr asn ala tyr ala phe pro thr ile pro leu
GCA TCT ATG TTC GTT TTT TCT ATT GCT ACA AAT GCC TAT GCA TTC CCA ACT ATA CCA CTA

ser arg leu phe asp ala met leu arg ala his arg leu his gln leu ala phe asp
TCT CGT CTA TTC GAT AAC GCT ATG CTT CGT GCT CAT CGT CTT CAT CAG CTG GCC TTT GAC

thr tyr gln gln phe glu glu ala tyr ile pro lys glu gln lys tyr ser phe leu gln
ACC TAC CAG GAG TTT GAA GAA GCC TAT ATC CCA AAG GAA CAG AAG TAT TCA TTC CTG CAG

Fig. 5.

GAATTCAACTTCTCCATACTTTGGATAAGGAAATACAGACATGAAAAATCTCATTTGCTGAGTTGTTATTTAAGCTTGCC

CAAAAAGAAGAAGAGTCGAAAGAAGCTGTGTGCGCAGGTAGAAAGCTTTGGAGATTATCGTCACCTGCAATGCTTCGCAATA

TGGCGCAAAATGACCAACAGCGGTTGATTGATCAGGTAGAGGGGCGCTGTACGAGGTAAAGCCGATGCCAGCATTCC

TGACGACGATACGGAGCTGCTGCGGATTACGTAAAGAAGTTATTGAAGCATCCTCGTCAGTAAAAAGTTAATCTTTTC

AACAGCTGTCATAAAGTTGTCACGGCGGAGACTTATAGTCGCTTTGTTTTTATTTTTTAAATGTAATTTGTACATGGAGAA

AP - SD

-21 -20
met lys gln ser thr ile ala leu ala leu pro leu phe thr pro val
AATAAA GTG AAA CAA AGC ACT ATT GCA CTG GCT CTC TTA CCG TTA CTG TTT ACC CCT GTG

1
thr lys ala phe pro thr ile pro leu ser arg leu phe phe asp asn ala met leu arg ala
ACA AAA GCC TTC CCA ACT ATA CCA CTA TCT CGT CTA TTC GAT AAC GCT ATG CTT CGT GCT

20
his arg leu his gln leu ala phe asp thr tyr gln glu phe glu ala tyr ile pro
CAT CGT CTT CAT CAG CTG GCC TTT GAC ACC TAC CAG GAG TTT GAA GAA GCC TAT ATC CCA

40
lys glu gln lys tyr ser phe leu gln asn pro gln thr ser leu cys phe ser glu ser
AAG GAA CAG AAG TAT TCA TTC CTG CAG AAC CCC CAG ACC TCC CTC TGT TTC TCA GAG TCT

17/18

0177343

Fig.6.

```

60   ile pro thr pro ser asn arg glu thr gln gln lys ser asn leu glu leu leu arg
    ATT CCG ACA CCC TCC AAC AGG GAG GAA ACA CAA CAG AAA TCC AAC CTA GAG CTG CTC CGC

70
80   ile ser leu leu ile gln ser trp leu glu pro val gln phe leu arg ser val phe
    ATC TCC CTG CTG CTC ATC CAG TCG TGG CTG GAG CCC GTG CAG TTC CTC AGG AGT GTC TTC

90
100  ala ash ser leu val tyr gly ala ser asp ser asn val tyr asp leu leu lys asp leu
    GCC AAC AGC CTA GTG TAC TAC GGC GCC TCT GAC AGC AAC GTC TAT GAC CTC CTA AAG GAC CTA

110
120  glu glu gly ile gln thr leu met gly arg leu glu asp gly ser pro arg thr gly gln
    GAG GAA GGC ATC CAA ACG CTG ATG GGG AGG CTG GAA GAT GGC AGC CCC CGG ACT GGG CAG

130
140  ile phe lys gln thr tyr ser lys phe asp thr asn ser his asn asp asp ala leu leu
    ATC TTC AAG CAG ACC TAC AGC AAG TTC GAC ACA AAC TCA CAC AAC GAT GAC GCA CTA CTC

150
160  lys asn tyr gly leu leu tyr cys phe arg lys asp met asp lys val glu thr phe leu
    AAG AAC TAC GGG CTG CTC TAC TAC TGC TTC AGG AAG GAC ATG ATG GAC AAG GTC GAG ACA TTC CTG

170
180  arg ile val gln cys arg ser val glu gly ser cys gly phe AM
    CGC ATC GTG CAG TGC TCT GTG GAG GGC AGC TGT GGC TTC TAG CTGCCC

190 191

```

Fig.6(Cont.)



European Patent
Office

EUROPEAN SEARCH REPORT

0177343

Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 85307044.9
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
D,A	INFECTION AND IMMUNITY, vol. 42, no. 1, October 1983, (Washington DC) R.N. PICKEN et al. "Nucleotide Sequence of the Gene for Heat-Stable Enterotoxin II of Escherichia coli" pages 269-275 * Totality * --	1,2,5	C 12 N 15/00 C 07 H 21/04 C 12 P 21/00 C 12 P 21/02 C 07 K 15/00 C 07 K 13/00 C 12 N 5/00 //C 12 R 1:19
D,A	JOURNAL OF BACTERIOLOGY, vol. 154, no. 1, April 1983 (Washington DC) S. MICHAELIS et al. "Mutations That Alter the Signal Sequenc of Alkine Phosphatase in Escherichia coli" pages 366-374 * Totality * --	1,18,19	
D,A	JOURNAL OF BACTERIOLOGY, vol. 149, no. 2, February 1982 (Washington DC) H. INOUE et al. "Signal Sequence of Alkine Phosphatase of Escherichia coli" pages 434-439 * Totality * --	1,18,19	C 12 N C 07 H C 12 P C 07 K
D,A	EP - A2 - 0 114 695 (YAMANE; THE CALPIS FOOD INDUSTRY CO., LTD.; MITSUI TOATSU CHEMICALS, INCORPORATED) * Abstract * --	1	
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
VIENNA		07-01-1986	WOLF
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

0177343

Application number

EP 85307044.9

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
D,A	<u>WO - A1 - 84/00 774</u> (PHARMACIA AB) * Abstract * --	1	
D,A	<u>EP - A2 - 0 022 242</u> (GENENTECH, INC.) * Abstract; claim 18; fig. 1,3 * & US-A-4 342 832 --	1,15, 16	
A	<u>EP - A2 - 0 112 012</u> (CASE WESTERN RESERVE UNIVERSITY) * Claim 1 * --	1	
A	<u>EP - A2 - 0 111 389</u> (GENENTECH, INC.) * Abstract; fig. 2 * ----	1	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
Place of search VIENNA		Date of completion of the search 07-01-1986	Examiner WOLF
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			